135 related articles for article (PubMed ID: 9549640)
1. Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir.
von Moltke LL; Greenblatt DJ; Grassi JM; Granda BW; Duan SX; Fogelman SM; Daily JP; Harmatz JS; Shader RI
J Clin Pharmacol; 1998 Feb; 38(2):106-11. PubMed ID: 9549640
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo.
von Moltke LL; Greenblatt DJ; Duan SX; Daily JP; Harmatz JS; Shader RI
J Pharm Sci; 1998 Oct; 87(10):1184-9. PubMed ID: 9758674
[TBL] [Abstract][Full Text] [Related]
3. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir.
Eagling VA; Back DJ; Barry MG
Br J Clin Pharmacol; 1997 Aug; 44(2):190-4. PubMed ID: 9278209
[TBL] [Abstract][Full Text] [Related]
4. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro.
Granfors MT; Wang JS; Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):79-85. PubMed ID: 16433896
[TBL] [Abstract][Full Text] [Related]
5. HIV protease inhibitors, saquinavir, indinavir and ritonavir: inhibition of CYP3A4-mediated metabolism of testosterone and benzoxazinorifamycin, KRM-1648, in human liver microsomes.
Inaba T; Fischer NE; Riddick DS; Stewart DJ; Hidaka T
Toxicol Lett; 1997 Dec; 93(2-3):215-9. PubMed ID: 9486958
[TBL] [Abstract][Full Text] [Related]
6. Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion.
Hesse LM; von Moltke LL; Shader RI; Greenblatt DJ
Drug Metab Dispos; 2001 Feb; 29(2):100-2. PubMed ID: 11159797
[TBL] [Abstract][Full Text] [Related]
7. Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions.
Decker CJ; Laitinen LM; Bridson GW; Raybuck SA; Tung RD; Chaturvedi PR
J Pharm Sci; 1998 Jul; 87(7):803-7. PubMed ID: 9649346
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors.
Iribarne C; Berthou F; Carlhant D; Dreano Y; Picart D; Lohezic F; Riche C
Drug Metab Dispos; 1998 Mar; 26(3):257-60. PubMed ID: 9492389
[TBL] [Abstract][Full Text] [Related]
9. Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes.
Eagling VA; Tjia JF; Back DJ
Br J Clin Pharmacol; 1998 Feb; 45(2):107-14. PubMed ID: 9491822
[TBL] [Abstract][Full Text] [Related]
10. CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro.
Eagling VA; Wiltshire H; Whitcombe IW; Back DJ
Xenobiotica; 2002 Jan; 32(1):1-17. PubMed ID: 11824416
[TBL] [Abstract][Full Text] [Related]
11. Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes.
Chauret N; Gauthier A; Nicoll-Griffith DA
Drug Metab Dispos; 1998 Jan; 26(1):1-4. PubMed ID: 9443844
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of human cytochromes P450 in vitro by ritonavir and cobicistat.
Hossain MA; Tran T; Chen T; Mikus G; Greenblatt DJ
J Pharm Pharmacol; 2017 Dec; 69(12):1786-1793. PubMed ID: 28960344
[TBL] [Abstract][Full Text] [Related]
13. Alprazolam-ritonavir interaction: implications for product labeling.
Greenblatt DJ; von Moltke LL; Harmatz JS; Durol AL; Daily JP; Graf JA; Mertzanis P; Hoffman JL; Shader RI
Clin Pharmacol Ther; 2000 Apr; 67(4):335-41. PubMed ID: 10801241
[TBL] [Abstract][Full Text] [Related]
14. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents.
Hsu A; Granneman GR; Bertz RJ
Clin Pharmacokinet; 1998 Oct; 35(4):275-91. PubMed ID: 9812178
[TBL] [Abstract][Full Text] [Related]
15. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes.
Wen X; Wang JS; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2002 Jan; 57(11):799-804. PubMed ID: 11868802
[TBL] [Abstract][Full Text] [Related]
16. Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole.
von Moltke LL; Durol AL; Duan SX; Greenblatt DJ
Eur J Clin Pharmacol; 2000 Jun; 56(3):259-61. PubMed ID: 10952482
[TBL] [Abstract][Full Text] [Related]
17. In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors.
Zalma A; von Moltke LL; Granda BW; Harmatz JS; Shader RI; Greenblatt DJ
Biol Psychiatry; 2000 Apr; 47(7):655-61. PubMed ID: 10745059
[TBL] [Abstract][Full Text] [Related]
18. Effect of Naltrexone Hydrochloride on Cytochrome P450 1A2, 2C9, 2D6, and 3A4 Activity in Human Liver Microsomes.
AlRabiah H; Ahad A; Mostafa GAE; Al-Jenoobi FI
Eur J Drug Metab Pharmacokinet; 2018 Dec; 43(6):707-713. PubMed ID: 29744741
[TBL] [Abstract][Full Text] [Related]
19. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction.
Kumar GN; Dykstra J; Roberts EM; Jayanti VK; Hickman D; Uchic J; Yao Y; Surber B; Thomas S; Granneman GR
Drug Metab Dispos; 1999 Aug; 27(8):902-8. PubMed ID: 10421617
[TBL] [Abstract][Full Text] [Related]
20. Apparent mechanism-based inhibition of human CYP3A in-vitro by lopinavir.
Weemhoff JL; von Moltke LL; Richert C; Hesse LM; Harmatz JS; Greenblatt DJ
J Pharm Pharmacol; 2003 Mar; 55(3):381-6. PubMed ID: 12724045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
